Holen Sie sich die Stockscreener-App
38.94
0.28%
0.11
Handel nachbörslich:
38.70
-0.24
-0.62%
Schlusskurs vom Vortag:
$38.83
Offen:
$38.74
24-Stunden-Volumen:
705.47K
Relative Volume:
0.57
Marktkapitalisierung:
$2.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-103.69M
KGV:
-20.96
EPS:
-1.8579
Netto-Cashflow:
$-70.46M
1W Leistung:
+6.42%
1M Leistung:
+32.27%
6M Leistung:
+91.82%
1J Leistung:
+108.35%
1-Tages-Spanne:
$38.74
$40.42
1-Wochen-Bereich:
$36.43
$40.42
52-Wochen-Spanne:
$13.30
$40.62
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
38.94 | 2.32B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Enliven Therapeutics stock hits 52-week high at 30.29 USD - investing.com
25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN) - Stock Titan
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Q1 EPS Estimate for Enliven Therapeutics Reduced by Analyst - MarketBeat
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Price-Driven Insight from (ELVN) for Rule-Based Strategy - news.stocktradersdaily.com
Enliven Therapeutics CMO Executes $1.2M Stock Sale | Company Update 2026News and Statistics - IndexBox
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - AOL.com
Volume Report: Should I trade or invest in Enliven Therapeutics Inc2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Enliven Therapeutics Insider Sold Shares Worth $1,404,024, According to a Recent SEC Filing - MarketScreener
Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares - Stock Titan
Aug PreEarnings: Can Enliven Therapeutics Inc disrupt its industryDip Buying & Low Volatility Stock Recommendations - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $56.00 at HC Wainwright - Defense World
ELVN Stock Soars as Merck’s Billion-Dollar Acquisition Validates Strategy - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Terns Pharmaceuticals (TERN) - The Globe and Mail
Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright - MarketBeat
Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade - MarketBeat
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Insider Monkey
Enliven Reports Q4 Loss; Clinical Milestones Ahead - timothysykes.com
Enliven Therapeutics (ELVN) affiliate files to sell 45,000 shares via Jefferies - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade - marketbeat.com
Enliven Therapeutics (NASDAQ:ELVN) Gains Attention After Price Target Adjustment - kalkinemedia.com
Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00 - MarketBeat
Clear Street reiterates Enliven Therapeutics stock Buy on CML opportunity By Investing.com - ca.investing.com
Enliven Therapeutics stock surges 28% on Merck-Terns deal By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
ELVN Surges 12%: Clinical Milestone Breaks Barriers and Sparks Biotech Momentum - Bitget
Mizuho raises Enliven Therapeutics price target to $45 on CML data - Investing.com Canada
Enliven Therapeutics (Nasdaq: ELVN) founder files Form 144 to sell 100,000 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month HighShould You Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 By Investing.com - Investing.com Canada
Enliven Therapeutics CMO Collins sells $138,800 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CMO Collins sells $138,800 in stock - Investing.com
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% HigherHere's What Happened - MarketBeat
Enliven Therapeutics stock hits 52-week high at $30.98 - Investing.com
(ELVN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC - MarketBeat
Energy Moves: Should I trade or invest in Enliven Therapeutics IncEarnings Recap Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Enliven Therapeutics (ELVN) CMO sells 40,000 shares after option exercise - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock - MarketBeat
CFO of Enliven (NASDAQ: ELVN) sells 10,000 common shares - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):